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Immunohistochemical determination of oestrogen receptor: comparison of
different methods of assessment of staining and correlation with clinical
outcome of breast cancer patients
DM Barnes, WH Harris, P Smith, RR Millis and RD Rubens
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Summary Immunohistochemical staining for oestrogen receptor (ER) has been carried out using antibody ER
ID5 on 170 women who received first-line tamoxifen treatment for evaluable metastatic breast cancer. ER
status had been determined some years previously, using a ligand-binding cytosol assay. The adequacy of the
tissue used for the cytosol assay was always checked by histology on an adjacent block and was deemed to be
typical of the tumour overall as was the block used for immunohistochemistry. Six different methods were used
to assess the degree ofstaining and comparisons were made to determine which method gave the most clinically
relevant results. Clinical outcome was assessed both in terms of duration of response to tamoxifen determined
by log-rank analysis and type of response using the chi-squared test. The ER immunohistochemical assay gave
superior results compared with the cytosol assay, with all of the subjective methods of assessment of staining
giving statistically significant correlations with clinical outcome. The additional contribution of progesterone
receptor (PR) staining with antibody NCL PGR was also studied.
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Oestrogen receptors (ERs) have been measured in human
mammary carcinoma tissue for almost 30 years and ER
status is generally recognised as being a useful prognostic and
predictive factor. The presence of ER is related to an
improved overall survival and a favourable response to
endocrine treatment for metastatic disease. Initially, for
clinical purposes, ER was measured on tumour tissue
cytosols using a ligand-binding assay (LBA) with Scatchard
analysis (Korenman and Dukes, 1970). The cytosol assay
presents some problems however, the most important of
which is the need to take great care to ensure that tumour
tissue is transported and stored at low temperature to prevent
loss of binding activity. Other problems include the amount
of tissue required, the length of time taken to complete the
assay and the limited number of samples that can be
measured at any one time. Histological confirmation of the
quality of tissue used for assay is not always possible and in
some samples the tumour tissue is inevitably diluted by
surrounding stroma and occasionally necrotic material giving
erroneously low or negative results. Conversely, low positive
results can occasionally be obtained from ER-negative
tumours with strongly positive cells in surrounding normal
breast ducts.
It was realised that these problems could be overcome by
the use of specific antibodies against the ER protein. It took
some time, however, before the first of such antibodies were
developed by Greene and colleagues in 1980 and their use in
a cytosol enzyme immunoassay (EIA) described by King et
al. (1985). The availability of anti-ER antibodies also created
the opportunity for the development of immunohistochemical
assays on tissue sections. The first commercial ER
immunohistochemical assay (ERICA) was available in kit
form from Abbott Laboratories using antibody H222 on
frozen tissue sections. The use of enzyme antigen retrieval
techniques was of limited success in applying this antibody to
routinely fixed tissue.
However, the recent introduction of antibodies such as ER
ID5 (Al Saati et al., 1993) which can be used on fixed,
paraffin-embedded sections after heat-mediated antigen
retrieval, has recently changed the situation dramatically.
Instead of being carried out in biochemistry or clinical
chemistry laboratories, assays can now be done as part of the
routine histopathological assessment of breast tumour tissues.
In parallel with the development of antibodies to ER has
been the production of antibodies to progesterone receptors
(PRs). Unlike ER, the original PR antibody KD68 (Press and
Greene, 1988), available from Abbott Laboratories, worked
satisfactorily on formalin-fixed paraffin-embedded tissue as
well as on frozen tissue (Bobrow et al., 1994). Other
antibodies to PR e.g. NCL PGR have now been produced
which also give good results on fixed material (Taylor et al.,
1994) after antigen retrieval and are generally less expensive.
As with the introduction of all new techniques, the results
obtained with these latest immunohistochemical assays had
to be validated against results from established LBA
techniques. There are several published studies in which this
has been done and they show generally good agreement
between the overall findings with the two methods (Andersen
et al., 1990; Saccani Jotti et al., 1994). Early studies using the
immunohistochemical assay on fixed tissue sections suggest
that the results are clinically relevant (Goulding et al., 1995;
Veronese et al., 1995). However, there is no general
agreement as to how the immunohistochemical assay should
be evaluated and several different methods for scoring
sections have been described (Kinsel et al., 1989; Remmele
and Stegner, 1987; Reiner et al., 1990). Now that antibodies
like ER ID5 have opened up the possibility of many
retrospective and prospective studies there is a pressing need
for quality assurance of both the technical reproducibility of
staining and the method of assessment. The first is relatively
easy, provided that adequate positive and negative controls
are used, but the second is much more difficult to achieve. It
is extremely important that agreement on a scoring method
should be reached so that comparisons can be made between
results obtained from different laboratories.
We have used ER ID5 to stain formalin-fixed paraffin-
embedded tissue sections of mammary carcinoma tissue from
170 women treated with tamoxifen for metastatic disease.
Evaluation of ER using immunohistochemistry has been
compared with results obtained from the LBA on tumour
tissue cytosol. We have further used several different ways of
evaluating stained tissue sections in an attempt to ascertain
which is the most clinically relevant. We have also looked at
Correspondence: DM Barnes
Received 23 October 1995; revised 18 March 1996; accepted 19
March 1996Immunohistochemical determination of oestrogen receptor
DM Barnes et al
1446
the additional value of assessing PR status by immunohis-
tochemistry to find out whether this improves the clinical
predictive ability of ER.
Materials and methods
Patients
The study group consisted of 170 women who received first-
line tamoxifen treatment for evaluable metastatic breast
cancer. A total of 133 patients had presented with operable
primary disease (41 had node-negative disease, 86 node-
positive disease and in six the node status was not known), 23
had locally advanced disease and 14 had distant metastases at
presentation. None of the patients had received prior
adjuvant systemic therapy.
The patients have been followed-up for a median of 16.6
years (range 1-17.6 years). Diagnosis and date of recurrence
was determined in a standard manner according to the
criteria of Hayward et al. (1978) and response to treatment
was assessed by UICC criteria (Hayward et al., 1977).
Response was classified as either complete/partial (respon-
ders) or static/progressive disease (non-responders). Results
obtained on a subset of these patients have been described
previously (Barnes and Millis, 1995). Patients' details are
given in Table I.
Histological assessment
Tumours were typed according to WHO criteria. Histological
grade was determined by one of the authors (RRM)
according to the method of Bloom and Richardson with
modifications as suggested by Elston (1984). (Table I).
Table I Patient characteristics
Age at diagnosis
Mean
Range
Tumour size
Mean
Range
Menstrual status
Pre
Peri
Post
Other
Stage
Operable node negative
Operable node positive
Nodes unknown
Locally advanced
Metastatic
Histology
Infiltrating ductal
GI
GII
GIII
Infiltrating lobular
Other
Nodal status of operable cases
Negative
1-3 positive
> 3 positive
ER status
Cytosol assays
Negative
Positive
Histo score
0-100
> 100
Other methods
Negative
Positive
56 years
27-77 years
4.01 cm
0-17 cm
40 (24%)
35 (21%)
92 (54%)
3 (1%)
41 (24%)
86 (51%)
6 (3%)
23 (14%)
14 (8%)
2 (1%)
92 (54%)
52 (31%)
18 (11%)
6 (3%)
41 (32%)
40 (32%)
46 (36%)
44 (26%)
126 (74%)
58 (34%)
112 (66%)
32 (19%)
138 (81%)
Oestrogen and progesterone receptor status
Oestrogen receptor status was determined in two ways. The
dextran-coated charcoal LBA was performed at the time of
presentation on breast tumour cytosols (King et al., 1979)
prepared from either primary tumour tissue (n= 156) or
metastatic lesions (n = 14). Tissue adjacent to that taken for
the cytosol assay was always assessed histologically to ensure
that it was representative of the tumour as a whole.
Retrospective immunohistochemical assay was performed on
routine formalin-fixed paraffin-embedded tissue sections
which had been taken from the above. As an attempt was
always made to cut sections from a block which contained
some normal ducts, inevitably the two assays were frequently
carried out on different pieces of tissue. The receptor status in
infiltrating carcinomas is generally consistent throughout the
tumour and within metastases therefore the fact that different
blocks were used in some cases should not be of relevance.
PR was only determined retrospectively by immunohisto-
chemistry.
Immunohistochemical assay
Sections of tumour were placed onto APES or vectabond-
coated slides and dried for 60 min at 56°C. After blocking
endogenous peroxidase activity, sections were placed in a
plastic rack in a microwaveable dish containing 0.01 M citrate
buffer, pH 6.0. Sections were microwaved for 3 x 10 min on
70% power in a 800 watt microwave oven and then removed
and allowed to cool to room temperature. After rinsing in
distilled water, followed by 0.01 M phosphate-buffered saline
pH 7.6 (PBS), sections were covered with 20% normal rabbit
serum in PBS to block non-specific binding. ER ID5
monoclonal antibody (Dako) diluted 1:100 in PBS was
applied for 1 h at room temperature. After thorough rinsing
in PBS ( x 3) sections were covered with FAB 2 biotinylated
rabbit anti-mouse Ig antibody (Dako) diluted 1: 200 with 3%
normal human serum in PBS for 30 min. Sections were then
rinsed and peroxidase-conjugated streptavidin (Dako) diluted
1: 500 in PBS was applied for 30 min. After further rinsing in
PBS, peroxidase activity was demonstrated with a solution of
hydrogen peroxide/diaminobenzidine and sections were then
lightly counterstained with haematoxylin, dehydrated, cleared
and mounted.
Controls
Positive and negative controls were always included in every
run. A specifically prepared tissue block was used as
positive control. This was made from slices of tissue from
two tumours with different levels of receptor activity. A
negative control, in which primary antibody was omitted,
was included for each sample. When selecting tumour
material for assay an attempt was always made to use a
block which included some normal breast tissue. This acts
an excellent internal control as usually at least a few
individual normal cells are ER-positive and their presence
in a non-staining tumour can confirm genuine ER
negativity.
Immunohistochemical assay for PR
Immunohistochemical staining for PR was carried out using
essentially the same method as for ER except that the anti-
PR antibody NCL-PGR (Novacastra Laboratories Ltd) was
used at a dilution of 1 in 40.
Assessment of receptor status
Ligand-binding assay A cut-off point of 20 fmol mg-' of
cytosol protein was used for the cytosol assay. This was the
standard cut-offpoint in the Unit since, over a long period of
time and study, this was found to be the most clinically
relevant figure.
IImmunohistochemical assay Staining was assessed individu-
ally by two of the authors (DMB and WH). Disagreement
was uncommon (<5% of samples) but when it occurred
slides were re-evaluated jointly at a double-headed micro-
scope and agreement reached.
Positive staining was scored in several different ways:
1 Any positive staining at any intensity.
2 Histo score (Kinsel et al., 1989). The intensity of staining
ofdifferent areas of the section was assessed and allocated
a value of 0 (nil), 1 (weak), 2 (distinct) or 3 (strong). The
percentage of positive cells in each of the staining
categories was also evaluated. The percentage of positive
cells was then multiplied by the intensity value and the
score of the products added together to give the H score,
which thus has a maximum of 300. A cut-off point of 100
was taken to differentiate between positive and negative as
was suggested by the authors of the paper first describing
the method.
3 The consistency or otherwise of staining was recorded as
negative, heterogenous positive or homogeneous positive
throughout a tumour.
4 The total proportion of cells staining positively at any
intensity was scored as 0 (no cells staining), 1 (when 1-
25% cells stained), 2 (when 26-50% cells stained), 3
(when 50-75% cells stained) or 4 (when >75% cells
stained).
5 The intensity was scored according to the overall
appearance as judged at different powers of magnifica-
tion, i.e. 0, none (no staining); 1, weak (only visible at
high power magnification); 2, moderate (visible at low
power magnification); 3, strong (striking even at low
power magnification). This was later termed the 'category'
score.
6 For some evaluations this system was simplified and the
cases subdivided into 'negative' or 'positive'; 'negative'
tumours included those with either negative or only weak
staining while 'positive' tumours showed moderate or
strong staining.
The proportion and intensity scores (methods 4 and 5)
were also combined in different ways.
7 The scores were multiplied together to give a range of 1-
12 similar to the immunoreactive score (IRS) first
described by Remmele and Stegner (1987).
8 These scores were added together to give the 'quick score'
as used by Reiner et al. (1990), with a range of 2-7.
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Results
Response to tamoxifen, complete or partial was seen in 87/170
(51%) of cases. This high proportion of women showing a
positive response is almost certainly due to the prior selection
of patients in the study which was based on their known
response to hormone treatment. Since the purpose ofthe study
was to relate ER status to response women with unevaluable
disease were excluded. The actual percentage of patients with
ER-positive tumours depends upon both the method of assay
and the method of assessment of staining. The cytosol assay
with a cut-off of 20 fmol mg-' found 126/170 (74%) of
tumours to be positive. The immunohistochemical assay using
the histo score with a cut-off of 100 found 112/170 (65%) of
cases to be positive. With all of the other methods of
evaluation, 32/170 (19%) of cases were totally negative and
81% showed some level ofstaining, but the overall number of
tumours designated as positive or negative depended on the
method ofevaluation used. As seen in Table II the proportion
of positive cases ranged from 31% (IRS) to 69% (simplified
category score) (strong+moderate). Using the simplified
category score, 58 cases (34%) were PR-positive. This is a
lower proportion than is usually found in an unselected group
of patients where approximately 50% of the cases are PR-
positive. Examples of positive staining patterns are shown in
Figure 1.
The Kaplan-Meier plots in Figure 2 show that all the
methods of assay and evaluation of ER gave significant
results when used to predict the duration of response. The
cytosol assay gave the lowest level of significance (X2 11.91,
P<0.001). All of the immunohistochemical methods gave
chi-squared values of over 30 with the histo score giving the
lowest value (X2 30.31 P<0.0001) and the category score the
highest (X2 49.44 P<0.0001).
Similarly when the relationship between different ways of
measuring and assessing ER status and type of response was
examined, using the chi-squared test the cytosol assay again
gave the lowest level ofsignificance with a response rate of58%
in the women with ER-positive tumours (X2 7.89, P=0.005)
(Table III). The immunohistochemical assay gave results which
werehighly significant in relation to responseirrespective ofthe
method of assessment with chi-squared values ranging from
21.07 for the histo score (64% ofER-positive casesresponding)
to 31.51 for the category score (69% responders). The addition
of PR measured by immunohistochemistry refines the
information provided by ER. For example, when tumours
were divided into positive and negative using the simplified
Staining for PR was only evaluated using the category and
simplified category scores.
Statistics
At the outset of the statistical analysis log-rank curves
according to the method of Kaplan and Meier (1958) were
run for each of the subjective methods of scoring (apart from
the histo score) using different combinations of values. The
ones chosen for the definitive analysis were those which gave
a good separation between patients with different clinical
outcomes. The relationships between the different methods of
evaluation of ER status and clinical outcome were assessed in
various ways. The duration of response to treatment with
tamoxifen, i.e. from start of treatment to progression of
disease, was determined by log-rank analysis. The chi-
squared test was used to examine both the relationship
between the results of different methods of ER assay and
evaluation as well as the association between receptor status
and type of response to treatment. A Cox multivariate
analysis was used to find which factors made an independent
contribution to the prediction of clinical outcome. The
Spearman rank correlation test was used to compare the
relationship between type of response and each of the scoring
methods for ER using continuous variables.
Table II Relationship between different methods of assessing ER
and percentage of ER-positive tumours
Cut off ER-positive
Assay (range) (%)
Any positive staining > 1% 81
(0-100%)
Histo score > 100 66
(0-300)
Consistency 100% 45
(<100% or 100%)
Proportion >75% 48
(0- 100%)
Category score (intensity) > 1 81
(0-3)
Modified category score >2 69
(<1 or >2)
IRS 12 31
(0-12)
Quick score > 5 48
(0-7)
LBA >20 fmol mg-' 74
(0-?)Immunohistochemical determination of oestrogen receptor
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Figure 1 (a) Infiltrating lobular carcinoma showing strong positive homogeneous staining for ER in >75% ofcells. (b) Infiltrating
ductal carcinoma showing moderate heterogeneous staining for ER. (c) Strong positive staining for ER in a normal breast duct in
an ER-negative infiltrating ductal carcinoma. (d) Infiltrating ductal carcinoma showing strong heterogeneous staining for PR in an
ER-negative tamoxifen-responsive tumour.
category score for both ER and PR, 33/46 (72%) of double
positive cases responded. However, 43/71 (61%) ofER-positive
PR-negative cases also responded so lack of PR does not
preclude a favourable response (Table IV).
Correlation with other prognosticfactors
The relative influence on time to progression of recognised
clinical and histopathological prognostic factors was exam-
ined in the multivariate Cox model. Firstly, the model was
run on the 128 patients for whom node status was known to
assess the relative importance of clinical features excluding
ER. The factors included were menstrual status, histological
type and grade, tumour size and nodal status; only the first
two were significant in both univariate and multivariate
models (Table Va). A second model was run on all the
patients in the study with the results of the different methods
of ER evaluation being treated as continuous variables; also
included were menstrual status and histological type and
grade. In univariate analysis each factor was found to be
significantly related to time to progression. The immunohis-
tochemical methods all gave very similar, highly significant
values. Because of the inter-relationship between the different
immunohistochemical scoring methods their place in the
multivariate model was interchangeable. In this analysis the
quick score gave a result which was marginally more
significant than the rest. Other features which in the final
analysis made independently significant contributions were
the cytosol ER assay and histology. (Table Vb). The
inclusion of the cytosol assay may at first sight appear
surprising but it is well recognised that the greater number of
receptor sites the greater is the likelihood of a favourable
outcome. Cytosol assays do have the advantage that they
measure the total number of sites while the immunohisto-
chemical assay is less sensitive at high levels.
The Spearman rank correlation test showed close inter-
relationships between type of response and all of the ER
methods of the assay and evaluation. A correlation coefficient
of 0.338 was found for the cytosol assay and values ranging
from 0.403 for consistency of staining to 0.431 for the quick
score were found for the immunohistochemical assays.
Comparison of results obtained by different methods of
evaluation
There were highly significant associations between the cytosol
assay and the immunohistochemical assays, e.g. the cytosol
assay compared with the histo score (X2 32.72, P<0.0001),
the cytosol assay compared with the category score (X2 40.25,
P<0.0001). There was agreement between the cytosol assay
and the immunohistochemical assay, irrespective of the
method of evaluation in 137 of the 170 cases (81%). There
were 33 cases with discordant results. Thirteen were definitely
positive by immunohistochemistry but were negative by the
cytosol assay. Eight showed no immunostaining at all but
had low positive cytosol values (range 22-54, mean
42 fmol mg-'); four of these eight cases had appreciable
amounts of positive staining in normal ducts in the sections
studied. The remaining 12 cases all showed focal weak (11
cases) or moderate (one case) immunostaining with histo
scores less than 100 and had low positive (ten cases) or
negative (two cases) cytosol results.
Comparison of ER status and response
There were 14 patients with inappropriate ER results who
responded to tamoxifen. In one case the immunohistochem-
istry was negative and the cytosol value was 54 fmol mg-'. In
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Figure 2 (a? Time to progression as a function of ER status measured by cytosol ligand-binding assay using a cut-off of
20fmol mg cytosol protein. (b) Time to progression as a function of ER status determined immunohistochemically and evaluated
using the Histo score with a cut-off of 100. (c) Time to progression as a function of ER status according to the quick score. (d) Time
to progression as a function of ER status according to the category score (-ve, negative; w, weak; m, moderate; s, strong).
the other 13 cases cytosol values were negative, three were
also ER-negative by immunohistochemistry (but two were
PR-positive), the others all showed immunostaining with two
being weak, five moderate and three strong stainers.
There were 41 cases with positive ER results both by
cytosol assay and by immunohistochemistry (22 with strong
staining and 19 with moderate staining), who failed to
respond to tamoxifen. All of these patients had one or more
of the following poor prognostic features: PR negativity,
large tumour size or heavy nodal involvement, the latter two
showing that when the tumour burden is overwhelming ER
status has little influence on disease outcome.
Discussion
These results are in agreement with the findings of Goulding
et al. (1995) and confirm that highly significant clinical
information can be obtained from the determination of ER
using an immunohistochemical evaluation. Whatever scoring
method is used, in this study we show that immunohisto-
chemistry gives superior results to the cytosol assay as it is
more closely related to patient outcome. The ligand binding
assay was done up to 17 years ago and there has been a
general improvement in cytosol assays since the early days.
Although it is perhaps unfair to compare methodology of 17
years ago with a current immunohistochemical technique it is
also true to say that one of the consequences of the general
improvement in cytosol assays has been an increase in the
number of cases found to be positive which has resulted in
some reduction in the sensitivity of the technique. In the
present study we have shown that immunohistochemistry can
give results which are clinically relevant, a very important
factor now that small tumours are being diagnosed with
increasing frequency and no tissue is available for the cytosol
assay. Another advantage of the histological method on
paraffin-embedded tissue is that the cellularity of the tumour
can be taken into consideration when evaluating the staining
(Underwood, 1983).
All the methods of scoring used in this study with ER ID5
gave significant results, therefore the method of choice will
depend upon further studies into which is the most acceptable
and gives the most consistent intra- and inter-observer
reproducibility. It is important to select a method which is
easy and quick to apply and is reproducible. In our own
laboratory, we have had considerable discussions as to
whether the proportion or intensity of staining of cells is
the best parameter. Immunohistochemists have an inherent
scepticism about the significance of intensity of staining as
this is known to be affected by staining methods. However
strict attention to methods and comparison with controls can
overcome this to some extent. Evaluation of the proportion
of stained cells on the other hand can also be subjective as
well as being affected by technique. Only experience and
interlaboratory studies will determine which method is the
most appropriate. This study has shown that there is little to
choose between the different methods of scoring. The chi-
squared test relating ER status to type of response found
results with the category score to be the most significant. In
the Cox multivariate analysis for time to progression with ER
staining treated as a continuous variable the quick score was
more significant than the rest.
For over 15 years a quality assurance scheme for ER
cytosol assays has been organised within Europe by the
European Organisation for the Research and Treatment of
Cancer (EORTC). Pilot studies are under way to develop a
2-
0)
._4
CO
Q)
0
a
0 z
0
a,,
a
0
0
0 a 0
zImmunohistochemical determination of oestrogen receptor
DM Barnes et al
1450
Table III Relationship between different methods of assay and evaluation and response to tamoxifen
Response
Complete/partial
n %
Cytosol assay
0-20 fmol mg-
>20 fmol mg 1
Histo score
0-100
> 100
Consistency of staining
Negative
Heterogeneous
Homogeneous
Proportion
Negative
75%
>75%
IRS
Negative
1-11
12
14 32
73 58
15 26
72 64
4
32
51
4
28
55
4
45
38
Quick score
Negative
1-5
6-7
Category score
Negative
Weak
Moderate
Strong
Simplified category score
Negative and weak
Moderate and strong
4
28
55
4
7
33
43
13
52
67
13
48
68
13
52
73
13
50
67
Staticl
progressive disease
n
30
53
43
40
28
30
28
28
41
14
28
41
14
28
28
27
13
34
61
69
11 21
76 65
28
14
22
19
42
41
Table IV Relationship between combined ER and PR status
(simplified category score; negative and weak vs moderate and
strong) and response to tamoxifen treatment
Response
Staticl
Complete! progressive
partial disease Total
n % n n %
ER/PR status
ER- PR- 8 20 33 41 24 X2=30.03
ER- PR+ 3 20 9 12 7 P<0.0001
ER + PR- 43 61 28 71 42
ER+ PR+ 33 72 13 46 27
87 51 83 170
similar scheme for ER on formalin-fixed paraffin-embedded
tissue. In the UK the National External Quality Assessment
Scheme (NEQAS) for quality control in diagnostic immuno-
histochemistry is well established and this scheme has recently
included ER in their assessments and it is of interest to note
that improvements in the quality and consistency of staining
were already apparent in the second round results.
The correct cut-off point for ER assays has been debated
over the years. In resolving this issue the reason for doing the
assay must always be borne in mind. Is ER being measured
to identify women who are likely to benefit from endocrine
therapy as either an adjuvant therapy for early disease or as
treatment for metastatic disease or is it being used as a
marker of prognosis? When considering prediction of
response in the case of metastatic disease, it should be
remembered that only 30 to 40% of all patients will respond
to hormone treatment. This is a much lower level than the
Table V Cox multivariate analyses showing which factors are
significantly related to the prediction of clinical outcome
Univariate Multivariate
x P-value x2 P-value
a
Menstrual status 6.6 0.01 4.9 0.03
Histology 7.7 0.006 7.7 0.006
Tumour size 3.5 0.06
Nodal status 0.3 0.6
b
Menstrual status 10.8 0.001 3.7 0.06
Histology 8.0 0.005 4.7 0.03
ER cytosol 23.8 <0.001 5.9 0.02
IRS 37.3 <0.001
Quick score 41.8 <0.001 41.8 <0.0001
H score 36.7 <0.001
Simplified category 38.7 <0.001
score
Category score 39.9 <0.001
incidence of ER positivity. In the early days of the assay this
discrepancy was not so marked but as more was learnt about
the extreme care which needs to be taken over storage
conditions and assay procedures, the sensitivity of the assays
has improved and the proportion of patients found to have
ER-positive tumours has increased. But does this make the
results more clinically relevant?
It should also be noted that both the absolute amount of
ER and the proportion of ER-positive tumours increases with
age. In order to take account of this Jensen and DeSombre
(1993) have suggested that tumours should be described as
ER-rich and ER-poor. Maybe we should revert to this for
Total
n %
44
126 74
59
112 66
32
62
76 45
32
57
81 48
32
86
52 31
32
56
82 48
X2=7.89
P=0.005
x2=21.07
P<0.0001
X2=26.88
P<0.0001
x2 28.32
P<0.0001
X2=29.19
P<O0.000
X2=27.48
P<0.0001
32
21
55
62
x2= 31.51
P<O0.000
36
53
117 69
%2=26.79
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immunohistochemical results. Our results show that the more
positive staining there is the greater the likelihood of a
favourable response and with less staining fewer patients will
respond.
When it became obvious that not all ER-positive tumours
respond to hormone treatment other indicators of response
were sought. Horwitz and McGuire (1975) suggested that PR,
an oestrogen-induced protein, should also be measured. The
theory was that the coexpression of PR would indicate that
the ER in the tumour was functionally active. In practice, the
measurement of the two receptors does improve predictive
accuracy: ER-positive PR-positive tumours have approxi-
mately 80% likelihood of responding whereas double-
negative tumours have a less than 10% likelihood of
response (Stewart et al., 1982). However, half of the ER-
positive PR-negative tumours also show a favourable
response. Therefore if, as has been suggested, only PR
status was evaluated a significant number of patients who
would respond might be denied endocrine treatment. Our
results in this study are consistent with these findings. More
recently other oestrogen-induced proteins such as cathepsin D
and PS2 have been studied but neither of these alone or in
combination with ER have proved to be outstandingly
successful in refining response prediction.
The use of immunohistochemistry for the measurement of
ER has many advantages, some of which have been outlined
above. Not least is the great reduction in cost of the assays
which have followed the introduction of the newer
antibodies. In the current times of financial stringency, this
factor is of increasing relevance. The assay is now easier to
do and the results should become more reliable with
improvements in quality control. It is likely that ER will
have a continuing role in the management of patients with
breast cancer and interlaboratory consistencies will improve
as agreement is reached as to the best method of scoring.
Nevertheless, the assays should only be carried out when the
results are going to be of either practical clinical or research
value.
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